Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $61.85, for a total value of $432,950.00. Following the completion of the transaction, the insider directly owned 33,377 shares in the company, valued at $2,064,367.45. This trade represents a 17.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Wednesday, April 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $66.12, for a total value of $462,840.00.
• On Monday, March 16th, Joana Goncalves sold 7,641 shares of Oruka Therapeutics stock. The shares were sold at an average price of $40.91, for a total value of $312,593.31.
• On Tuesday, February 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $32.37, for a total value of $226,590.00.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $61.93 on Friday. The firm has a market capitalization of $3.73 billion, a PE ratio of -31.92 and a beta of -0.20. The business’s fifty day moving average price is $55.17 and its 200 day moving average price is $39.33. Oruka Therapeutics, Inc. has a 12 month low of $9.40 and a 12 month high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. As a group, equities analysts anticipate that Oruka Therapeutics, Inc. will post -2.2 EPS for the current year.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds have recently made changes to their positions in the company. Fairmount Funds Management LLC grew its holdings in shares of Oruka Therapeutics by 9.9% during the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock worth $71,252,000 after purchasing an additional 333,340 shares during the last quarter. Viking Global Investors LP purchased a new position in shares of Oruka Therapeutics during the third quarter worth about $51,280,000. Deep Track Capital LP grew its holdings in shares of Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after purchasing an additional 735,983 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Oruka Therapeutics by 38.1% during the fourth quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock worth $74,366,000 after purchasing an additional 676,865 shares during the last quarter. Finally, RTW Investments LP grew its holdings in shares of Oruka Therapeutics by 5.8% during the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock worth $62,382,000 after buying an additional 112,499 shares during the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Analyst Ratings Changes

ORKA has been the topic of several recent analyst reports. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 16th. Stifel Nicolaus increased their target price on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. Barclays raised their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, April 27th. BTIG Research reaffirmed a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a report on Thursday. Finally, Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a report on Thursday, April 30th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $120.80.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.